The Tecnimede Group

The Tecnimede Group, established in 1980, is a Portuguese pharmaceutical entity dedicated to the comprehensive lifecycle management of medications. This includes robust research and development, precise production, and strategic commercialization of pharmaceutical products. The company focuses on addressing critical health challenges, offering a portfolio exceeding 130 products designed for cardiovascular and metabolic diseases, neurodegenerative disorders, and infectious diseases. With a commitment to innovation, The Tecnimede Group holds over 440 patents and has filed 4,311 Marketing Authorization Applications (MAAs), underscoring its significant contribution to global healthcare solutions. Their operations are supported by a dedicated team, and you can learn more by visiting Meet The Tecnimede Group's team.

Operating with 500 - 1,000 employees across 3 locations, The Tecnimede Group manages a diverse product range that includes generic and specialized pharmaceutical offerings. The company's scale is further demonstrated by its substantial revenue of $171.7M. This operational capacity enables them to serve a broad spectrum of clients, primarily healthcare providers and patients requiring advanced therapeutic treatments. Their strategic focus on quality and efficacy ensures that their pharmaceutical solutions meet rigorous international standards.

The Tecnimede Group's market reach is extensive, exporting its pharmaceutical products to over 100 countries worldwide. This global presence highlights their role as a significant player in the international pharmaceutical landscape. Their business model is geared towards providing essential medications and innovative treatments, contributing to public health initiatives across various continents. The company's long-standing history and continuous investment in R&D position it as a reliable partner in the healthcare sector.